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Objective: To investigate the impact of French CF practice guidelines on patient
follow-up at four CF care centers between 1996 and 2005 (three years after
implementation of the guidelines in 2002).
Methods: Descriptive analysis of all patients (361 children and 301 adults) followed
up in one of the CF centers between 1996 and 2005. Retrospective collected data
included clinical characteristics, spirometry, microbiological tests and antibiotic
therapy.
Results: The average age at diagnosis was 3.7±8.0 years old. 38.1% of the patients
had a diagnosis suggested by respiratory problems. The average age of the patients
was 13.6±9.3 years in 1996 and 15.8±10.4 years in 2005 (p< 0.01). 52% of the
children had at least three scheduled visits at a center in 1996 versus 87% in
2005 (p< 0.05). This comparison was also signiﬁcant in the adult population: 59%
in 1996 and 72% in 2005 (p< 0.05). Aerosol therapy was administered to 69%
of the patients in 1996 versus 82% in 2005 (p< 0.01). Concerning respiratory
function, there was no signiﬁcant improvement: 64% of adults had %FEV1<80%
in 1996 and in 2005 whereas in children, the ﬁgures were 56% and 64% respectively.
Primocolonization with Pseudomonas aeruginosa was detected in 51% of patients
in 1996 and 55% in 2005 (no signiﬁcant difference). The average annual number of
courses of antibiotic therapy per patient increased signiﬁcantly between 1996 and
2005 (respectively 1.6±2.0 versus 2.4±2.1).
Conclusion: The implementation of national guidelines seems to have impacted
clinical practices. This study must be continued to show improvement in clinical
evolution of the patients.
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Survival, nutritional status, lung function and the quality of life in CF are indicators
of the overall quality of a given health care system. The post-WWII isolation
from W. Europe led to stagnation in all spheres of life. Modern treatment was
fully accessible to our patients only after 1989. A group of 639 patients diagnosed
between 1960 and June 2007 at our CF Centre, was divided into 3 cohorts according
to their year of birth. Cohort I comprised 187 patients born prior to 1975, while
Cohort II included 165 patients born between January 1, 1976 and December 31,
1985. Cohort III consists of 287 patients born after January 1, 1986. This cohort
was further divided into 2 subgroups, comprising patients born pre- and post-
January 1996. We have analysed semi-longitudinal anthropometric and spirometric
data in each category by t-test. Differences in survival between each group were
compared using Kaplan–Meier’s function of survival and utilising the “Long Rank”
test. High mortality rate, poor nutritional status, which especially worsens during
puberty and growth retardation were characteristic for the oldest cohort. However,
modern treatment schemes, already applied in Cohort II, led to the improvement
of nutritional status, central airway obstruction and increased median of survival
from 16.3 to 25.3 years. Modern treatment from early childhood in Cohort III led to
further improvement of peripheral airway obstruction and markedly longer survival.
Current intensive treatment from early childhood lowers childhood mortality to a
minimum. By this “unwanted experiment” we have conﬁrmed the importance of
intensive modern treatment, applied from the early infant period.
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The Czech Republic has a population of 10,230,000 inhabitants and is an ethnically
relatively homogeneous country. 471 Czech CF patients (224 males and 247
females) aged 0.1 to 53.1 years (median 14.5 years, 38.2%, older than 18 years
of age) are treated in 7 CF Centres (CFC). The main “reference” CFC is in
Prague (University Hospital Motol), that closely collaborates with regional CFCs
in faculty hospitals in major cities (Hradec Kralove, Pilsen, Brno and Olomouc),
including large district hospitals (Most and Ostrava). The post-WWII four decade
isolation of our country from the W. European development in the area of CF
diagnostics and care was a substantial handicap. However, in the past 17 years we
have managed to “catch up” by aggressive treatment and implementation of all
European best practice guidelines. The most frequent mutations comprise F508del
(66.7%), CFTRdele2,3(21kB) (5.4%), N1303K (2.2%) and 3849+10kbC>T and
G551D (2.1%), G542X (1.7%) and 1898+1G>A (1.3%). Currently, nutritional
status of the majority of our patients is in the range of normal values: median
body height −0.7 SD (range −3.4, 2.8 SD), weight −0.7 SD (−4, 2.6 SD), BMI
−0.5 SD (−3.7, 2.9 SD), median FEV1 79% pv (range 17, 144% pv). Height of our
youngest cases since 1999 at the 5 years of age is merely −0.3 SD and none of
these are below population speciﬁc norms. Furthermore, median FEV 1 in these
cases is 97% predicted. CF teams in our country work together and operate entirely
within all relevant international guidelines. The survival of our patients and their
quality of life has been improving signiﬁcantly within the last decade. Thus, we
assert that newly diagnosed cases in our country have the same starting point for
long-term survival and quality of life as their peers in Western Europe.
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Cystic ﬁbrosis is the second most common autosomal recessive disorder in the
Caucasian population. However, the disease was regarded as either a rare entity or
as non-exciting within the Arab population for many decades. This perception can
be attributed to missing awareness among physician and the absence of diagnostic
tools. We investigated the epidemiology of cystic ﬁbrosis in the administrative
region of North Al Bathina, one of the 10 administrative health care districts in
Oman. During 2000 to 2007, 26 patients have been diagnosed with cystic ﬁbrosis
in the central referring hospital, the teaching hospital of Oman Medical College.
This accounts for 3.2 new cystic ﬁbrosis cases per year in a total population of
approximately 450,000 inhabitants. With 6,766 births/year, the carrier frequency
in North Al Bathina is 1:25.5. This ﬁnding, which is similar to the Caucasian
carrier frequency of 1:25−30, has to be viewed with conservative caution. Due
do a high degree of consanguinity in the population, pedigrees are very complex
and limit the application of Hardy Weinberg. The phenotype in the cystic ﬁbrosis
population is severe. The average life expectancy is very low (12 years on average).
Preliminary molecular biological investigations point to the CFTR mutation S549R
and delF508. In addition to cystic ﬁbrosis, other genetic disorders (thalassemia,
ectodermal dysplasia, isovaleric acedimia) are present at the same time in 3 nuclear
families. A more detailed molecular diagnosis of our patient population will reveal
the speciﬁc aspects of cystic ﬁbrosis in the region in the future.
